A widely used diabetes medication, SGLT2 inhibitors, has shown a surprising benefit for cancer patients—protecting their ...

AstraZeneca's Imfinzi perioperative regimen improved event-free survival in gastric and GEJ cancer. The trial showed a strong ...

Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...

The Food and Drug Administration (FDA) has approved Tevimbra® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the ...

A new research paper was published in Oncotarget, Volume 16, on February 18, 2025, titled “Leukopenia, weight loss and oral ...